FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy.

Our aim was to analyse whether biomarkers extracted from baseline F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior systemic treatment, BRAF wild type, explored using F-FDG PET were included retrospectively. Our primary endpoint was overall survival (OS).